<DOC>
	<DOCNO>NCT01179217</DOCNO>
	<brief_summary>The purpose research test effect L-glutamine red blood cell patient Sickle Cell Anemia Sickle ß0-Thalassemia . Glutamine part protein part person 's normal diet . It often use nutritional supplement medication various medical problem intestinal problem . The benefit participate study may decrease pain problem cause sickle cell disease .</brief_summary>
	<brief_title>A Phase III Safety Efficacy Study L-Glutamine Treat Sickle Cell Disease Sickle βo-thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Patient least five year age . Patient diagnose sickle cell anemia sickle ß°thalassemia ( document hemoglobin electrophoresis ) . Patient least two documented episode sickle cell crisis within 12 month screen visit . If patient treat antisickling agent within three month screen visit , therapy must continuous least three month intent continue duration study . Patient patient 's legally authorize representative give write informed consent . If patient female childbearing potential , agree avoid pregnancy study willing agree practice recognize form birth control course study ( e.g . barrier , birth control pill , abstinence ) . Patient significant medical condition require hospitalization ( sickle cell crisis ) within two month screen visit . Patient prothrombin time INR &gt; 2.0 . Patient serum albumin &lt; 3.0 g/dl . Patient receive blood product within three week Screening Visit . Patient uncontrolled liver disease renal insufficiency ( refer Appendix 3 guideline ) . Patient pregnant lactating intention become pregnant study ( female childbearing potential ) . Patient currently take treat form glutamine supplement within 30 day screen visit . Patient treat experimental antisickling medication/ treatment within 30 day screen visit ( exception hydroxyurea pediatric patient ) . Patient currently take treat investigational drug within 30 day screen visit ( exception hydroxyurea pediatric patient ) . Patient currently enrol investigational drug device study and/or participate study within 30 day screen visit . There factor would , judgment investigator , make difficult patient comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Sickle Cell Pain Crises</keyword>
	<keyword>Painful Crises</keyword>
	<keyword>Sickle Cell Pain</keyword>
	<keyword>Vaso-occlusive Crises</keyword>
</DOC>